DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zbmqp4/liver_cancer) has announced the addition of the "Liver Cancer - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cancer and special features on late-stage and discontinued projects.
the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Companies Mentioned
Partial list of the 140+ companies mentioned in this comprehensive report:
- Acceleron Pharma
-
Active Biotech
- Bayer
-
Bio-Cancer Treatment International
- Caladrius Biosciences
- Can-Fite BioPharma
-
Daiichi Sankyo
-
Eisai
- F. Hoffmann-La Roche
-
Gamida Cell
-
Hutchison MediPharma
- Immune Network
- Jasco Pharmaceuticals
-
KAHR medical
- Keystone Nano
-
Les Laboratoires Servier
- MaxCyte
- MedImmune
- Nanobiotix
-
NeoPharm
-
Omeros
-
Omnitura Therapeutics
- Panacea Pharmaceuticals
- Qu Biologics
- Quimatryx
-
Raptor Pharmaceuticals
- Regulus Therapeutics
- Sirnaomics
- Synta Pharmaceuticals
-
Taiwan Liposome
- Targetome
- VasGene Therapeutics
- Vaxon Biotech
-
Welichem Biotech
-
Zhejiang BetaPharma
For more information visit http://www.researchandmarkets.com/research/zbmqp4/liver_cancer
